Merck & Co. Inc. (MRK) and Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved Steglatro (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 or SGLT2 inhibitor, and the fixed-dose combination Steglujan (ertugliflozin and sitagliptin) tablets.
from RTT - Biotech http://ift.tt/2BRe4EK
via IFTTT
No comments:
Post a Comment